Number of times cited according to CrossRef: 120. The aim of this study was to compare the clinical efficacy and safety of low dose cyproterone acetate-estrogen combination (Diane®) and the 5α-reductase inhibitor finasteride in … In my own opinion, Finasteride would have the least amount of negative side effects (memory fog, gynecomastia, depression, loss of libido), Spironolactone second (hyperkalemia, which can lead to a variety of symptoms including sudden cardiac arrest, and dizziness or syncope from dehydration), and Cyproterone Acetate (depression and liver damage) seems to more … Cyproterone acetate is a chlormadinine acetate derivative that has both progestational and antiandrogenic activity, … We found that cyproterone acetate, finasteride, and spironolactone were similarly effective in reducing the Ferriman–Gallwey score. Published by Elsevier Inc. All rights reserved.ScienceDirect ® is a registered trademark of Elsevier B.V. The androgenic profile did not change significantly during treatment.In patients with idiopathic hirsutism, the short-term results of treatment with cyproterone acetate, finasteride, and spironolactone are similar, but spironolactone is effective for a longer time.We use cookies to help provide and enhance our service and tailor content and ads. Relative to … Department of Obstetrics and Gynecology, Arash Maternity Hospital, Tehran University of Medical Sciences, Tehran, IranDepartment of Obstetrics and Gynecology, Arash Maternity Hospital, Tehran University of Medical Sciences, Tehran, IranDepartment of Obstetrics and Gynecology, Arash Maternity Hospital, Tehran University of Medical Sciences, Tehran, IranDepartment of Obstetrics and Gynecology, Arash Maternity Hospital, Tehran University of Medical Sciences, Tehran, IranDepartment of Obstetrics and Gynecology, Arash Maternity Hospital, Tehran University of Medical Sciences, Tehran, IranDepartment of Obstetrics and Gynecology, Arash Maternity Hospital, Tehran University of Medical Sciences, Tehran, IranUse the link below to share a full-text version of this article with your friends and colleagues.

ScienceDirect ® is a registered trademark of Elsevier B.V.Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutismPresented at The Endocrine Society 83rd Annual Meeting, Denver, Colorado, June 20–23, 2001.Copyright © 2003 American Society for Reproductive Medicine. Citing Literature.

Abstract Objectives: To compare the clinical and hormonal effects of finasteride and a combination regimen of cyproterone acetate (CPA) plus ethinyl estradiol (EE2) in … One year after therapy, the Ferriman–Gallwey score of patients who used spironolactone was significantly lower (6.74 ± 1.41) than that of patients who used either cyproterone acetate (7.92 ± 1.08), or finasteride (9.08 ± 0.99). By continuing you agree to the Copyright © 2020 Elsevier B.V. or its licensors or contributors. If you do not receive an email within 10 minutes, your email address may not be registered,

and you may need to create a new Wiley Online Library account.Enter your email address below and we will send you your usernameIf the address matches an existing account you will receive an email with instructions to retrieve your username

I repeat I do NOT want to grow my breasts at all so what do I do and what dose should I take P.s consulting a doctor isn't available since I live in a country where the LGBTQ people could be arrested and …

Overview. Follow-up was done at the end of therapy.Ferriman–Gallwey score before treatment, at 6 and 12 months of treatment, and 1 year after the end of treatment, and androgenic profile before and after treatment.At the end of therapy, the Ferriman–Gallwey score decreased by 38.9%, 38.6%, and 38.5% in patients who used cyproterone acetate, finasteride, and spironolactone, respectively. Bicalutamide was the third NSAA to be marketed, with flutamide and nilutamide preceding, and followed by enzalutamide. Bicalutamide and the other nonsteroidal antiandrogens (NSAAs), since their introduction, have largely replaced cyproterone acetate (CPA), an older drug and steroidal antiandrogen (SAA), in the treatment of prostate cancer. In the finasteride group, 280 (6.4%) men had prostate cancer with Gleason scores of 7-10 detected on needle biopsy vs 237 (5.1%) men in the placebo group.

Sixty-six hirsute women were randomized and treated with 1) flutamide (n = 15), 250 mg/day; 2) finasteride (n = 15), 5 mg/day; 3) ketoconazole (n = 16), 300 mg/day; and 4) ethinyl estradiol (EE)-cyproterone acetate (CPA; n = 20), 0.01 mg EE/day for the first week, 0.02 mg EE/day for the second week, and 0.01 mg EE/day for the third week, followed by a pause of 7 days, then 12.5 …